Abstract
A novel, whole-cell enzyme-linked immunosorbent assay (ELISA) based on a non-type-specific anti-human papillomavirus (HPV) E6 antibody was tested on 182 residual cytological specimens. For samples with a designation of more severe than cervical intraepithelial neoplasia grade 3 (CIN3+), 83% tested positive for E6; in a subset with paired testing for E6 ELISA and HPV DNA, 72% tested E6 positive and 92% tested high-risk (HR)-HPV DNA positive (P=0.2). Among the women with a less than CIN3 diagnosis, 31% and 47% tested positive for E6 and HR-HPV DNA, respectively (P=0.0006).
Original language | English (US) |
---|---|
Pages (from-to) | 1474-1479 |
Number of pages | 6 |
Journal | Clinical and Vaccine Immunology |
Volume | 19 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2012 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Clinical Biochemistry
- Microbiology (medical)